Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback

Phase 2positiveXTMAB-16Positive

AI Analysis

Summary

Xentria advances XTMAB-16 clinical development in pulmonary sarcoidosis following positive Phase 2 Part A data showing acceptable pharmacokinetics, safety, and immunogenicity, informing a proposed Part B amendment.

Clinical Trial Data

Phase

Outcome Details

XTMAB-16-201 Part A pharmacokinetic exposure, target-coverage, immunogenicity, safety and feasibility findings provided basis for further clinical evaluation

Importance:6/10

Sentiment:

0.60

clinical developmentFDA feedbackpharmacokineticssafetyimmunogenicity

Related Companies

$INBP $CBDY

Read the original article

Published by PR Newswire Clinical Trials on September 1, 2026 11:00 AM

Read Original